CN102093309A - Novel crystal forms of Febuxostat and preparation method of novel crystal forms - Google Patents
Novel crystal forms of Febuxostat and preparation method of novel crystal forms Download PDFInfo
- Publication number
- CN102093309A CN102093309A CN 201110027282 CN201110027282A CN102093309A CN 102093309 A CN102093309 A CN 102093309A CN 201110027282 CN201110027282 CN 201110027282 CN 201110027282 A CN201110027282 A CN 201110027282A CN 102093309 A CN102093309 A CN 102093309A
- Authority
- CN
- China
- Prior art keywords
- febustat
- crystal
- crystal forms
- crystal formation
- febuxostat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical chemistry, particularly relates to three crystal forms comprising H, I and J of 2-(3-cyan-4-isobutoxy)phenyl-4-methyl-5-thiazole formic acid (Febuxostat) and a preparation method of the three crystal forms. The invention also provides X-ray powder diffraction characteristic absorption peaks and infrared absorption peaks of the three crystal forms. The characteristic absorption peaks occur at the reflected angles 2 theta of about 6.71, 7.19, 10.03, 11.10, 12.96, 13.48, 15.78, 17.60 and 22.15 degrees in an X-ray powder diffraction pattern of the crystal forms. The invention further relates to a pharmaceutical composite containing the novel crystal forms and application of the novel crystal forms in preparation of medicaments for treating over-high uric acid-related diseases.
Description
The application is that Chinese application number is 200610095263.0, and the applying date is on December 7th, 2006, and denomination of invention is divided an application for the application for a patent for invention of " crystal formation of Febustat and preparation method thereof ".
Technical field
The invention belongs to the pharmaceutical chemistry technical field, be specifically related to new crystal H, the I of 3 kinds of Febustat (febuxostat) and J and preparation method thereof, contain the pharmaceutical composition of these 3 kinds of new crystal, and the utilization that is used for making the medicine of the too high relevant disease of treatment and blood uric acid.
Technical background
Febustat (Febuxostat), its chemistry is by name: 2-(3-cyano-4-isobutoxy) phenyl-4-methyl-5-thiazole formic acid.
Chemical structural formula:
Febustat has been submitted the new drug registration at U.S. FDA, is used for the treatment of and the too high diseases associated of uric acid, as gout, is used for reducing the uric acid of blood.Febustat has multiple crystal formation, and Chinese patent CN1275126 has put down in writing by the A that relates to this compound, the B of Japanese Supreme Being people company invention, C, D, G and amorphous and preparation method thereof.Wherein, crystal A exists with metastable-state crystal; Crystal B is made by drying under reduced pressure by hydrate G; Crystal C prepares by the polymorphic conversion of solvent mediation; Crystal D is a methylate, and it obtains through recrystallization from the mixed solvent of methanol solvate or methyl alcohol and water formation under the low-temperature reduced-pressure condition; Crystal G is a hydrate.According to Infrared spectroscopy, crystal A has the characteristic absorbance that itself and other crystal formation tagma branch can be come at about 1678cm-1; Crystal B about 1715,1701 and 1682cm-1 have the characteristic absorbance that itself and other crystal formation tagma branch can be come; Crystal C about 1703 and 1705cm-1 have the characteristic absorbance that itself and other crystal formation tagma branch can be come; Crystal D has the characteristic absorbance that itself and other crystal formation tagma branch can be come at about 1705cm-1; And crystal G about 1703 and 1684cm-1 have the characteristic absorbance that itself and other crystal formation tagma branch can be come.The inventor is in research Febustat process, it is unexpected that the discovery Febustat also exist other 3 kinds of crystal formations, these crystal formations are different from the disclosed 6 kinds of crystal formations of CN1275126 any, these 3 kinds of crystal habits that new crystal is not moisture and other solvent, its crystal formation has good stability, is fit to preparation technical process and long storage.
Summary of the invention
Purpose of the present invention provides the crystal formation of 3 kinds of Febuxostat news.
The crystal formation of first kind of Febustat of the present invention, this crystal formation are named the type into H, and its x-ray ray powder diffraction (XRPD) charateristic avsorption band (2 θ) value is about 6.71,7.19, and 10.03,11.10,12.96,13.48,15.78,17.60 and 22.15 °; See Fig. 1.This crystal through infrared analysis about 2238,1701,1678 and 1116cm
-1The place has the charateristic avsorption band that itself and other crystal formation difference can be come, and sees Fig. 2.
The new crystal of second kind of Febustat disclosed by the invention, this crystal formation are named the type into I, and x-ray ray powder diffraction (XRPD) charateristic avsorption band (2 θ) value of this crystal formation is about: 3.28,6.58,12.70,13.34,19.97,24.26 and 25.43 °, see Fig. 3.This crystal is through infrared analysis, and its infrared spectrogram is about 1730,1253 and 1097cm
-1The place has the charateristic avsorption band that itself and other crystal formation difference can be come, and sees Fig. 4.
The new crystal of the third Febustat disclosed by the invention, this crystal formation are named the type into J, and x-ray ray powder diffraction (XRPD) charateristic avsorption band (2 θ) value of this crystal formation is about: 3.07,12.25,13.16,25.21 and 26.86 °, see Fig. 5.This crystal is through infrared analysis, and its infrared spectrogram is about 1686 and 1655cm
-1The place has the characteristic absorbance that itself and other crystal formation difference can be come, and sees Fig. 6.
Among the present invention, the mensuration of 2 θ values is used CuK α light source, precision is ± 0.2 °, therefore, " pact " in above-mentioned " x-ray ray powder diffraction (XRPD) charateristic avsorption band (2 θ) value of crystal formation is about " should be defined as 2 θ ± 0.2 °, represent above-mentioned 2 θ values of getting to allow certain reasonably limit of error, its limit of error is ± 0.2 °.
Another object of the present invention is the preparation method who discloses Febuxostat new crystal forms.
The preparation method of Febuxostat crystal form H of the present invention, its process comprises: it is 1: 30～1: 100 R that Febustat is dissolved in mass volume ratio (grams per milliliter)
1In the CN solvent, heating for dissolving, the water bath heat preservation crystallization, holding temperature is 15～50 ℃, filters, the following 100 ℃ of dryings of normal pressure 12 hours obtain crystal formation H, wherein, R
1Expression alkyl or haloalkyl replace ethyl as methyl, ethyl, propyl group, chlorine, and particular compound can be acetonitrile, propionitrile, butyronitrile and chloroethyl nitrile etc., and preferred solvent is acetonitrile, propionitrile or their mixture.Following R
1Definition identical therewith.
Above-mentioned Febustat and R
1The mass volume ratio of CN solvent is preferably 1: 40, and the water bath heat preservation temperature is preferred 25 ℃ during crystallization.The preparation method of Febuxostat crystal form I of the present invention, its process comprises: it is 1: 30～1: 100 R that Febustat is dissolved in mass volume ratio (grams per milliliter)
1In the CN solvent, heating for dissolving, under the stationary state, 20-60 ℃ of decompression extracted solvent out to crystallization, and preferred 50 ℃, filter, 80 ℃ of crystal formation I that drying obtained in 24 hours reduce pressure; Wherein, R
1Define the same; Preferred solvent is acetonitrile, propionitrile or their mixture; Febustat and R
1The mass volume ratio of CN solvent is 1: 50, wherein, and R
1In the definition.The method of Febuxostat crystal form J of the present invention, its process comprises: it is 1: 30～1: 100 R that Febustat is dissolved in mass volume ratio (grams per milliliter)
1In the CN solvent, after the heating for dissolving, leave standstill crystallization, behind the suction filtration, under the normal pressure, room temperature is separated out behind the heating and melting, obtains crystal formation J, wherein, and R
1In the definition, preferred solvent is acetonitrile, propionitrile or their mixture, wherein Febustat and R
1The mass volume ratio of CN solvent is 1: 30.
Another purpose of the present invention provides a kind of pharmaceutical composition, comprise crystal formation H, crystal formation I or crystal formation J and the pharmaceutically acceptable auxiliary material or the carrier of the Febustat of effective therapeutic dose of the present invention, wherein the median size of Febuxostat crystal form is below 50 μ m more than the 1 μ m.But the dosage form oral preparations of said pharmaceutical composition, injection and external preparation; Oral preparations can be tablet, capsule, particle, control slow releasing tablet or capsule, intraoral disintegration, dissolving and dispersive tablet.Various preparations can adopt the known corresponding auxiliary material of persons skilled in the art, adopt corresponding known preparation of pharmaceutical formulations technology to make.Said effective therapeutic dose is 10～200mg, preferred 40～120mg.
Specifically, every dose of contained Febuxostat new crystal forms of the present invention is 20mg, 40mg, 80mg, 120mg in the above-mentioned said oral dosage form, and said " every dose " is representative every, every (capsule) etc., uses each 1～4 dose every day 1～2 time.
Pharmaceutical composition of the present invention can contain vehicle commonly used during for solid orally ingestible, such as tackiness agent, weighting agent, thinner, tablet agent, lubricant, disintegrating agent, tinting material, seasonings and lubricant, can carry out dressing to tablet in case of necessity.
Described weighting agent (vehicle) comprises lactose, N.F,USP MANNITOL, Xylitol, starch, pregelatinized Starch, W-Gum, Microcrystalline Cellulose, sorbyl alcohol, and they can use separately also can mix use.Aforementioned weighting agent is preferably lactose, N.F,USP MANNITOL, Microcrystalline Cellulose.
Described disintegrating agent comprises low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, polyvinylpyrrolidone, starch, Microcrystalline Cellulose, Xylo-Mucine, and they can use separately also can mix use.Aforementioned disintegrating agent is preferably low-substituted hydroxypropyl cellulose, starch, polyvinylpyrrolidone.
Described tackiness agent comprises the ethanolic soln of Vltra tears, hydroxypropylcellulose, polyvinylpyrrolidone, starch slurry, polyvinyl alcohol, Microcrystalline Cellulose, water, various concentration, and they can use separately also can mix use.The aforementioned adhesion agent is preferably the ethanolic soln of Microcrystalline Cellulose, Vltra tears, various concentration.
Described lubricant comprises stearic acid, Magnesium Stearate, calcium stearate, palmitinic acid, pure aluminium silicate, stearylamide, talcum powder, silicon-dioxide, and they can use separately also can mix use.Aforementioned lubricants is preferably Magnesium Stearate, pure aluminium silicate.
If necessary, other auxiliary materials can also be added, as sweeting agent, tinting material, odor mask, stablizer in pharmaceutical composition of the present invention.
Can prepare pharmaceutical composition of the present invention according to preparation any ordinary method that oral solid formulation adopted, as: wet granule compression tablet, encapsulated after direct powder compression, the granulation.Use conventional coating device, this pharmaceutical composition coating can be made film coated tablet or sugar coated tablet.Coated substrate comprises cellulose family, crylic acid resin, carbohydrate, as hydroxypropyl level methylcellulose gum, Eudragit L, sucrose.Also can add softening agent, antisticking agent, opalizer in this coated substrate.
In preparation pharmaceutical composition process of the present invention, the wetting agent that can add comprises ethylene glycol, propylene glycol, sorbyl alcohol and glycerine and fatty acid ester thereof, and these wetting agents can use separately or use with two or more any combination wherein.
Solid composite medicament of the present invention can be by carrying out granulation step, encapsulation step or film-making step and coating steps (if necessary) obtains with the routine dose form successively, is generally tablet, powder, the granule of tablet or surface coatings, the granule or the capsule dosage form of surface coatings.Said tablet comprises conventional sheet, slow releasing tablet, buccal tablet, orally disintegrating tablet, chewable tablet, effervescent tablet etc.
Pharmaceutical composition of the present invention can be by the preparation of pharmaceutics routine techniques.Can adopt wet granulation compressing tablet and dry powder direct tabletting method as tablet.
The present invention also provides H, I and the utilization of J crystal formation in making treatment and the too high diseases associated medicine of blood uric acid of Febustat, saidly mainly refer to the too high gout that causes of blood uric acid with the too high relevant disease of uric acid, the high blood uric acid that cancer patients's chemicotherapy causes, with and the too high illness of blood uric acid.
Through the animal kennel test, the crystal formation H of Febustat of the present invention, crystal formation I or crystal formation J all have the stronger activity of falling uric acid in the interior blood of body.
Description of drawings
Fig. 1 is the H crystal form X-x ray diffration pattern x of the embodiment of the invention 1 Febustat.
Fig. 2 is the H crystal formation infrared absorpting light spectra of the embodiment of the invention 1 Febustat.
Fig. 3 is the I crystal form X-x ray diffration pattern x of the embodiment of the invention 2 Febustat.
Fig. 4 is the I crystal formation infrared absorpting light spectra of the embodiment of the invention 2 Febustat.
Fig. 5 is the J crystal form X-x ray diffration pattern x of the embodiment of the invention 3 Febustat.
Fig. 6 is the J crystal formation infrared absorpting light spectra of the embodiment of the invention 3 Febustat.
Embodiment
The invention will be further described in conjunction with the embodiments, can make this area professional and technical personnel better understand the present invention, but the scope that does not limit the present invention in any way.
The 20g Febustat is placed two mouthfuls of flasks of 1000ml, add acetonitrile 800ml, to dissolving, treat that raw material dissolves fully in 80 ℃ of oil bath heated and stirred, stop heating, (20 ℃) oil bath insulation crystallization left standstill 2 hours under room temperature, filter,, obtain crystalline powder in 100 ℃ of vacuum-dryings 12 hours.Measure its X powder diffraction figure and infrared spectrogram, according to powder diagram and infrared absorption spectrum, that obviously generate is crystal formation H, sees Fig. 1 and Fig. 2.
Embodiment 2
The 20g Febustat is placed two mouthfuls of flasks of 2000ml, add acetonitrile 1000ml, heated and stirred treats that to dissolving raw material dissolves fully, stops heating, is evacuated to crystal in 50 ℃ of decompressions and separates out, and the 80 ℃ of dryings that reduce pressure 24 hours obtain crystalline powder.Measure its X powder diffraction figure and infrared spectrogram, according to powder diagram and infrared absorption spectrum, that obviously generate is crystal formation I, sees Fig. 3 and Fig. 4.
The 20g Febustat is placed two mouthfuls of flasks of 1000ml, add acetonitrile 600ml, heated and stirred treats that to dissolving raw material dissolves fully, stops heating, leaves standstill crystallization.Behind the suction filtration, after 210 ℃ of fusions of normal pressure, the room temperature crystallization. measure and infrared measurement through X powder diffraction, the X-powder diagram and the infrared absorption spectrum that obtain show that generating crystal formation is crystal formation J, sees Fig. 5 and Fig. 6.
Embodiment 4
The 20g Febustat is placed two mouthfuls of flasks of 2000ml, add propionitrile 1200ml, heated and stirred treats that to dissolving raw material dissolves fully, stops heating, is evacuated to crystal in 50 ℃ of decompressions and separates out, and the 80 ℃ of dryings that reduce pressure 24 hours obtain crystal formation I powder.
Embodiment 5
Febuxostat crystal form I capsule (specification: 120mg)
Prepare every as follows and contain 120mg Febustat capsule:
Prescription: Febustat I crystal formation 120g, butyleneglycol 1.2ml, starch 25g makes 1000.
Method: 120g Febustat H crystal formation, 25g starch is wetting with the 1.2ml 10% butyleneglycol aqueous solution, granulations of sieving after mixing, 60 ℃ of dryings, are filled adding to depress with capsule filling machine by whole.
Embodiment 6
Febuxostat crystal form H sheet
Prescription: Febustat H crystal formation 80g, pregelatinized Starch 110.5g, low substituted hydroxy-propyl methylcellulose gum 10.5g, Magnesium Stearate 0.8g, make 1000
Preparation technology: Febustat H crystal formation, pregelatinized Starch, low substituted hydroxy-propyl methylcellulose gum and Magnesium Stearate are crossed 100 orders respectively, mix compressing tablet.
Embodiment 7
Febuxostat crystal form J sheet
Prescription: Febustat J crystal formation 20g, starch 35g, polyvinylpyrrolidone 5.5g, Magnesium Stearate 0.5g, make 1000.
Preparation technology: Febustat J crystal formation, starch, polyvinylpyrrolidone and Magnesium Stearate are crossed 100 orders respectively, mix compressing tablet.
Stability test
Get H, I and the J crystal of Febustat respectively, every kind of crystal each minute gets to place in right amount and is numbered H1, I1, J1; H2,12, J2; H3, I3 in the plate of J3, splits (storage condition 1:4500lx ± 500lx illumination, storage condition 2:60 ℃ high temperature, storage condition 3: the stability test of carrying out relative humidity 92.5 high humiditys) under the following condition.Measurement result is shown in table 1～3.
Table 1 strong illumination study on the stability (4500lx ± 500lx)
Table 2 high temperature experiment study on the stability (60 ± 2 ℃)
Table 3 high humidity experiment study on the stability (RH90 ± 5%)
The result confirms that through infrared spectra and X-ray powder diffraction analysis infrared spectra and the X-ray powder diffraction of crystal formation H, I and J all do not change, and prove that it still keeps original crystal formation.
With compared before on-test, the total impurities during whole test in every kind of polymorphic does not change.Prove that crystal formation of the present invention is a quite stable, be suitable for the manufacturing and the secular storage of medicament.
Claims (8)
1. the crystal formation J of a Febustat, reflection angle 2 θ of this crystalline X-ray powder diffraction figure have located charateristic avsorption band being about 3.07,12.25,13.16,25.21 and 26.86 °.
2. crystal formation J as claimed in claim 1 is characterized in that: infrared spectrogram is about 1686 and 1655cm
-1There is charateristic avsorption band at the place.
3. method for preparing Febuxostat crystal form J, its process comprises: it is 1: 30～1: 100 R that Febustat is dissolved in mass volume ratio (grams per milliliter)
1In the CN solvent, after the heating for dissolving, leave standstill crystallization, behind the suction filtration, under the normal pressure, room temperature is separated out behind the heating and melting, obtains crystal formation J, wherein, and R
1Expression alkyl or haloalkyl.
4. method as claimed in claim 3 is characterized in that: Febustat and R
1The mass volume ratio of CN solvent is 1: 30.
5. as claim 3 or 4 described methods, said R
1The CN solvent is acetonitrile or propionitrile.
6. a pharmaceutical composition comprises claim 1 or 2 described Febuxostat crystal form J and pharmaceutically acceptable auxiliary material or carriers.
7. pharmaceutical composition as claimed in claim 6, the median size of Febuxostat crystal form J is below 50 μ m more than the 1 μ m.
8. claim 1 or the 2 described Febuxostat crystal form J utilization in the medicine of making treatment and the too high diseases associated of blood uric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110027282 CN102093309B (en) | 2006-12-07 | 2006-12-07 | Novel crystal forms of Febuxostat and preparation method of novel crystal forms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110027282 CN102093309B (en) | 2006-12-07 | 2006-12-07 | Novel crystal forms of Febuxostat and preparation method of novel crystal forms |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100952630A Division CN1970547B (en) | 2006-12-07 | 2006-12-07 | Novel febuxostat crystal form and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102093309A true CN102093309A (en) | 2011-06-15 |
| CN102093309B CN102093309B (en) | 2012-07-04 |
Family
ID=44126596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110027282 Active CN102093309B (en) | 2006-12-07 | 2006-12-07 | Novel crystal forms of Febuxostat and preparation method of novel crystal forms |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102093309B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415481B2 (en) | 2009-06-10 | 2013-04-09 | Teva Pharmaceuticals Usa, Inc. | Crystalline form of febuxostat |
| CN103467412A (en) * | 2013-09-30 | 2013-12-25 | 杭州朱养心药业有限公司 | Drug chemical compound for gout |
| WO2016091230A1 (en) | 2014-12-12 | 2016-06-16 | Zentiva, K.S. | Formulations containing a solid solution of febuxostat |
| CN114341120A (en) * | 2019-08-21 | 2022-04-12 | 国立大学法人东京大学 | ABCC11 inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009279A1 (en) * | 1990-11-30 | 1992-06-11 | Teijin Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
| PT1956014T (en) * | 1998-06-19 | 2019-04-24 | Teijin Pharma Ltd | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
-
2006
- 2006-12-07 CN CN 201110027282 patent/CN102093309B/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415481B2 (en) | 2009-06-10 | 2013-04-09 | Teva Pharmaceuticals Usa, Inc. | Crystalline form of febuxostat |
| US8609856B2 (en) | 2009-06-10 | 2013-12-17 | Teva Pharmaceuticals Usa, Inc. | Crystalline forms of Febuxostat |
| US8742129B2 (en) | 2009-06-10 | 2014-06-03 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of febuxostat |
| CN103467412A (en) * | 2013-09-30 | 2013-12-25 | 杭州朱养心药业有限公司 | Drug chemical compound for gout |
| WO2016091230A1 (en) | 2014-12-12 | 2016-06-16 | Zentiva, K.S. | Formulations containing a solid solution of febuxostat |
| CN114341120A (en) * | 2019-08-21 | 2022-04-12 | 国立大学法人东京大学 | ABCC11 inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102093309B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1970547B (en) | Novel febuxostat crystal form and its preparation method | |
| CN102050755B (en) | Novel agomelatine crystal forms and preparation methods of agomelatine crystal forms | |
| CN105769792A (en) | A tablet containing a 1-(beta-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound | |
| ZA200005153B (en) | Novel crystalline forms of an antiviral benzimidazole compound. | |
| JP6126040B2 (en) | Five crystal forms of nicosamide compound, its production method and its drug combination and use | |
| CN102093309B (en) | Novel crystal forms of Febuxostat and preparation method of novel crystal forms | |
| ZA200208162B (en) | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations. | |
| CN101759656B (en) | Febuxostat new crystal forms and preparation method thereof | |
| EP3653603A1 (en) | Fenlean (flz) crystal g form, preparation method, and composition and use thereof | |
| CN102453021A (en) | Novel crystal form of lenalidomide and preparation method thereof | |
| CN102093308B (en) | New crystal forms of Febuxostat and preparation methods thereof | |
| CN102453020A (en) | Novel crystal form of lenalidomide and preparation method thereof | |
| US5516773A (en) | Agent for treating high blood pressure and cardiac insufficiency | |
| WO2012055163A1 (en) | Letrozole type i crystal and preparation method thereof | |
| CN103664956A (en) | New crystal form of ticagrelor and preparation method thereof | |
| CN101899056A (en) | Prasugrel hydrobromide polymorph and preparation method thereof | |
| CN115124420B (en) | Rhein and matrine eutectic hydrate, preparation method, composition and application thereof | |
| CN101756981B (en) | Brufen loratadine pseudoephedrine release preparation and preparation method thereof | |
| DE602004010837T2 (en) | PHARMACEUTICAL COMPOSITION BASED ON IDAZOXANE SALT OR ITS POLYMORPHEN | |
| DE202021100039U1 (en) | Ethyl cellulose-coated particles containing a salt of tapentadol and phosphoric acid | |
| CN105669674A (en) | Ticagrelor new crystal form, and application thereof in medicine preparation | |
| CN109721557A (en) | Letrozole crystalline substance II type solid matter and preparation method and its pharmaceutical composition and purposes | |
| CN1080851A (en) | The reinforcing agent of somatostatin | |
| CN102093387B (en) | Crystal compound of 4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridine-3-alcohol-hydrate | |
| CN108203436A (en) | A kind of ticagrelor novel crystal forms S and its application in pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200720 Address after: 221001 south side of Dongshan, comprehensive zone, Jinshanqiao Development Zone, Xuzhou City, Jiangsu Province Co-patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP Co.,Ltd. Patentee after: XUZHOU WANBANG JINQIAO PHARMA Co.,Ltd. Address before: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Patentee before: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. |